Liège, Belgium, August 10, 2022 – 18:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, following the first draw by the Company in connection with the loan facility entered into with funds managed by Highbridge Capital Management, LLC (“Highbridge”) and funds managed by Whitebox Advisors, LLC (“Whitebox”, and together with Highbridge, each a “Lender”) , a first part of the commitment fee due by the Company was settled in new shares, and a first part of the loans was provided in kind by the Lenders against the issue of new shares.
On August 8, 2022, the Company and the lenders entered into a three-year senior convertible loan agreement for a maximum amount of EUR 100,000,000, to be drawn down in three tranches. The first tranche of EUR 50,000,000 was drawn upon signature of the agreement.